natgillin/translations-raw huggingface dataset:
The method according to claim 6, wherein the pain is selected from the group consisting of inflammatory pain, neuropathic pain, acute pain, chronic pain, visceral pain, migraine pain and cancer pain. 
Kombinacija prema zahtjevu 9, naznačena time da je bol odabrana od upalne boli, neuropatske boli, akutne boli, kronične boli, visceralne boli, boli zbog migrene, te boli zbog karcinoma.
The method of E 50, wherein the IL-23 antagonist is a monoclonal antibody or a monoclonal antibody fragment that binds to and inhibits the activity of IL-23p19 or IL-23R. 
1L-23 antagonist za uporabu u skladu sa zahtjevom 50, naznačen time, da IL-23 antagonist je monoklonsko antitijelo ili fragment monoklonskog antitijela koje se veže na i inhibira djelovanje IL-23p19 ili IL-23R.
The apparatus for converting carbon dioxide CO2 into carbon monoxide CO according to claim 1, wherein the process chamber of the CO2 converter is formed by an outlet pipe of the hydrocarbon converter, wherein the outlet pipe is connected to an inlet for CO2 gas. 
Uređaj za stvaranje sintetskog plina u skladu s jednim od patentnih zahtjeva 9 do 11, pri čemu je radna komora C pretvornika oblikovana izlaznom cijevi pretvornika ugljikovodika, pri čemu je izlazna cijev povezana na ulaz za vodu.
A method of delivering a warning in case of an approaching mobile emergency service, wherein the emergency service transmits emergency service signals, wherein a number of stationary emergency service communication devices are set up to receive emergency service signals, wherein at least one user receiver (R) associated with a user verifies whether an emergency service signal is being transmitted, and delivers a warning signal if an emergency service signal has been detected. 
Sustav prema zahtjevu 7 ili 8, pri čemu je korisnički prijemnik (R) opremljen drugim pojačalom signala (IF) koje pojačava signale koji su došli iz drugog pojasnog propusnog filtra (6) 1 šalje RSSI signal (signal koji reprezentira trenutnu razinu prijemnog RF signala). Metoda slanja upozorenja u slučaju približavanja neke mobilne hitne službe, pri čemu hitna služba šalje signale hitne službe dok je određeni broj fiksnih komunikacijskih uređaja hitne službe podešen tako da prima signale hitne službe, naznačena time
The use according to claim 1 or 2, where the medicament further comprises at least one administration unit C containing dose c of tapentadol, where dose b < dose c. 
Lijek prema patentnom zahtjevu 8 ili 9, naznačen time da nadalje sadrži najmanje jednu jedinicu za davanje C koja sadrži dozu c tapentadola, gdje je doza b < doze c, pri čemu se navedena najmanje jedna jedinica za davanje C daje tijekom trećeg intervala davanja od najmanje jedan dan nakon navedenog drugog intervala davanja.
The present inventors have also found that the initiation of martensitic transformation of the filler ingredient by means of application of ultrasound can advantageously be combined with the curing of the resin base by means of ultrasound. 
Ovaj izum je također našao da se inicijacija martenzitske transformacije sastojka za punjenje primjenom ultrazvuka pogodno može kombinirati s očvršćivanjem baze za smolu pomoću ultrazvuka.
A pharmaceutical compositions comprising a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically accepted carrier or excipients. 
Farmaceutski sastav, naznačen time, da obuhvaća terapeutski učinkovitu količinu spoja prema zahtjevu 11, zajedno s farmaceutski prikladnim nosačem ili pomoćnim sredstvom.
Preferably, though not necessarily, longitudinal blades 4 are spaced about longitudinal axis A of mixing member 1 so as to be equidistant from and equally spaced angularly about longitudinal axis A and so form a perfectly cylindrical "squirrel cage" structure. 
Pogodno, premda nije nužno, uzdužne lopatice 4 su razmaknute oko uzdužne osi A članka za miješanje 1 tako da budu na jednakoj udaljenosti i jednako kutno razmaknute oko uzdužne osi A 1 tako formiraju savršeno cilindričnu strukturu "krletke za vjevericu ".
Next, DCM (24mL) followed by MeOH (6mL) were added to the flask at room temperature. 
Nakon toga je dodan DCM (24 mL), zatim MeOH (6 mL), u tikvicu na sobnoj temperaturi.
Preparation process according to Claim 15, in which the said residue A is chosen from the group comprising halide, phosphate, sulfate, nitrate and organic carboxylate. Preparation process according to Claim 16, in which the said residue A is chosen from the group comprising chloride, bromide and iodide. 
16.Proizvodni postupak prema zahtjevu 15, naznačen time, da je navedeni ostatak A odabran iz skupine koju čine halid, fosfat, sulfat, nitrat i organski karboksilat, 17.Proizvodni postupak prema zahtjevu 16, naznačen time, da je navedeni ostatak A odabran iz skupine koju čine klorid, bromid 1 jodid.
The eggs and the milk are mixed with the sugar replacement composition. 
Jaja i mlijeko miješati sa sastavinom koja zamjenjuje šećer.
A jacketed tube comprising a metal tube (1,9,10,11,33,34,43), an outer jacket (2,12,42) surrounding the metal tube, and a tear cord (3,13,14,15,38,39,40,41,44) characterised in that the jacketed tube is for use in downhole applications relating to hydrocarbon extraction and is spoolable, in that the metal tube has a wall which is of hollow cylindrical shape and is smooth, solid, continuous, without break or interruption, is capable of being hermetically sealed and is suitable for connection to hermetically sealing compression fittings to convey fluids downhole, and in that the tear cord is positioned in communication with an outer surface of the metal tube and inside the diameter of the flexible outer jacket and is able to be pulled back to create a slit in the outer jacket to allow the outer jacket to be separated from the metal tube without damage to the metal tube surface. 
Obložena cijev, koja sadrži metalnu cijev (1, 9, 10, 11, 33, 34, 43), vanjsku oblogu (2, 12, 42) koja okružuje metalnu cijev, te žicu za kidanje (3, 13, 14, 15, 38, 39, 40, 41, 44), naznačena time što je obložena cijev namijenjena upotrebi kod bušotina za izvlačenje ugljikovodika i može je se namotati na kalem, što metalna cijev ima stijenku koja je oblika šupljeg valjka i glatka, puna, kontinuirana, bez prekida, može je se hermetično zabrtviti i pogodna je za povezivanje s kompresivnim spojnicama za hermetično brtvljenje, kako bi se dopremilo tekućine u bušotinu, te što se žica za kidanje nalazi u kontaktu s vanjskom površinom metalne cijevi i unutar promjera fleksibilne vanjske obloga i može je se izvući kako bi se dobilo izrez u vanjskoj oblozi, kako bi se omogućilo da se vanjska obloga odvoji od metalne cijevi bez oštećivanja površine metalne cijevi.
contacting a G protein-coupled receptor with an optionally labeled known ligand to the receptor in the presence or absence of a test compound, wherein the G protein-coupled receptor comprises an amino acid sequence selected from the group consisting of: amino acids 1-335 of SEQ ID NO:2; amino acids 2-335 of SEQ ID NO:2; 
(a) stavljanje u doticaj receptora vezanih G-proteina sa opcijski obilježenim poznatim ligandom za receptor, u prisutnosti ili u odsutnosti test spoja, pri čemu receptor vezanih G-proteina sadrži sekvencu amino kiseline odabranu iz skupine koja sadrži: (i) amino kiseline 1-335 od SEQ ID NO:2; (ii) amino kiseline 2-335 od SEQ ID NO:2;
The dispiro 1,2,4-trioxolane of claim 16, wherein the salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, camphorate, camphor sulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isothionate), lactate, maleate, methane sulfonate, nicotinate, 2-naphthalene sulfonate, oxalate, palmitoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluene sulfonate and undecanoate salt. 
Dispiro-1,2,4-trioksolan prema bilo kojem od patentnih zahtjeva od 1 do 12 pri čemu je sol izabrana iz grupe koju čine acetat, adipat, alginat, citrat, aspartat, benzoat, benzen sulfonat, bisulfat, butirat, kamforat, kamfor sulfonat, diglukonat, glicerofosfat, hemisulfat, heptanoat, heksanoat, fumarat, hidroklorid, hidrobromid, hidrojodid, 2-hidroksietansulfonat (izotionat), laktat, maleat, metan sulfonat, nikotinat, 2-naftalen sulfonat, oksalat, palmitoat, pektinat, persulfat, 3-fenilpropionat, pikrat, pivalat, propionat, sukcinat, tartrat, tiocijanat, fosfat, glutamat, bikarbonat, p-toluen sulfonat i undekanoatna sol.
The crystalline form of any one of claims 1-3 for use in treating and/or preventing a condition selected from schizophrenia, schizoaffective disorders, cognitive impairment accompanying schizophrenia, mild-to-moderate cognitive deficits, dementia, psychotic states associated with dementia, psychotic depression, mania, acute mania, bipolar disorder, paranoid and delusional disorders, dyskinetic disorders such as Parkinson's disease, neuroleptic induced parkinsonism, depression, anxiety, and drug abuse. 
Kristalni oblik prema bilo kojem od zahtjeva 1-3, naznačen time, da se upotrebljava za liječenje i/ili prevenciju stanja izabranih iz shizofrenija, shizoafektivni poremećaji, kognitivno pogoršanje koje prati shizofreniju, blago do umjereno kognitivno oštećenje, demencija, psihotična stanja povezana s demencijom, psihotična depresija, manija, akutna manija, bipolarni poremećaj, paranoidni i deluzijski poremećaji, diskinetički poremećaji kao što su Parkinsonova bolest, neuroleptički inducirani parkinsonizam, depresija, anksioznost i zloporaba droga.
A compound selected from the group consisting of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide; and pharmaceutically acceptable salts thereof for use in the treatment of pain. 
Spoj, naznačen time, da je izabran iz skupine koja se sastoji od (25)-(-)-N-(6-klor-2,3-dihidro-benzo[1,4]dioksin-2- ilmetil)-sulfamida; i njegove farmaceutski prihvatljive soli za upotrebu kod liječenja boli.
The antibody, or binding fragment thereof according to any one of Claims 1 to 6 or 9, or the pharmaceutical composition according to Claim 11 for use in treating a malignant tumor in an animal; and optionally wherein said animal is human. 
Farmaceutski sastav prema zahtjevu 18, naznačen time, da se upotrebljava u liječenju malignih tumora kod životinje; i prema potrebi kada je navedena životinja ljudsko biće.
at least one net (230) through which the air is absorbed by the chiller (100) is passed, 
- najmanje jednom mrežom (230) kroz koju se propušta zrak apsorbiran putem hladnjaka(100),
A cylinder lock as defined in claim 3, wherein said projecting key code contact surfaces (210 a, 211 a) are displaced from each other also sideways relative to said key plug axis. 
Cilindar brava kako je definirano u zahtjevu 22, naznačena time da su navedene izbočene stopice (210a, 211a) međusobno pomaknute također bočno u odnosu na navedenu os uloška za ključ.
The method of Claim 146 further comprising the step of: closing the crossover valve (150) after at least 5% of the total combustion of the gas has occurred. 
Postupak opisan patentnim zahtjevom 16, naznačen time što je dodatno uključeno da se: prijelazni ventil (150) zatvara nakon najmanje 5% ukupnog izgaranja plinova.
The power tool of claim 2, 3, 4, 5, 6, 7, 8, 9,10,11,12,13,14,15,16, 17,18,19, 20 or 21 including: the housing having at least a first and a second housing portion; the first housing portion including the impaction mechanism (250), partially or completely; the second housing portion including the multiplication mechanism (210), partially or completely; 
Električni alat u skladu s patentnim zahtjevom 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 ili 21, naznačen time što sadrži: kućište, koje u najmanju ruku ima prvi i drugi dio kućišta; gdje se u prvom dijelu kućišta, djelomično ili u potpunosti, nalazi udarni mehanizam (250); gdje se u drugom dijelu kućišta, djelomično ili u potpunosti, nalazi mehanizam za pojačanje (210);
The boards were coarsely planned in the equipment 60 for the coarse planing at the later adhesion surfaces, and were subsequently sorted, for example, manually or by means of the sorting equipment 61. 
Ploče su bile grubo poravnane u opremi 60 za grubo ravnanje na površinama koje se kasnije trebaju zalijepiti, i nakon toga su bile pohranjene, na primjer, ručno ili pomoću opreme za sortiranje 61.
binding of the antibody or fragment thereof to the first HER3 receptor in the absence of a HER3 receptor ligand reduces ligand-independent formation of a first HER3 receptor-second HER3 receptor protein complex in a cell which expresses first HER3 receptor and second HER3 receptor; or 
vezanje protutijela ili njegovog fragmenta na prvi HER3-receptor u odsutnosti liganda HER3-receptora, smanjuje tvorbu neovisnu o ligandu, proteinskog kompleksa od prvog HER3-receptora i drugog HER3-receptora, u stanici koja izražava prvi HER3-receptor i drugi HER3-receptor; ili
A stable aqueous aldehyde solution according to any one of claims 1 to 3 wherein the surfactant is an alcohol ethoxylate surfactant in a 0.1% to 25% m/v concentration. 
Stabilna vodena otopina aldehida u skladu s bilo kojim od patentnih zahtjeva 1 do 3 pri čemu je surfaktant alkoholni etoksilat surfaktant koncentracije od 0.1% do 25% m/v.
The method of claim 2 wherein the sequencing comprises massively parallel sequencing of the predefined subsequences. The method of claim 3 wherein said massively parallel sequencing comprises attaching DNA fragments to an optically transparent surface, conducing solid phase amplification of the attached DNA fragments to create a high density sequencing flow cell with millions of DNA clusters, and sequencing the DNA clusters by a four-color DNA sequencing-by-synthesis method employing reversible terminators with removable fluorescent dyes. 
Postupak prema zahtjevu 1, naznačen time da navedeno sekvenciranje obuhvaća vezanje DNK fragmenata za optički transparentnu površinu, provođenje umnožavanja vezanih DNK fragmenata na čvrstoj fazi da bi se stvorila sekvencirajuća protočna stanica velike gustoće s milijunima DNK klastera i sekvenciranje DNK klastera postupkom sinteze s četverobojnim DNK sekvenciranjem, u kojem se koriste reverzibilni terminatori s uklonjivim fluorescentnim bojama.
It is particularly preferred that said mono- or dicarboxylic acid is present in an aqueous form of the pharmaceutical formulation in a concentration of between ≧1 and ≦100 mM, preferably between ≧2 and ≦50 mM, and even more preferably between ≧5 and ≦25 mM. 
Formulacija prema zahtjevu 1, naznačena time, da se adipinska Kiselina ili adipat nalaze u vodenom obliku farmaceutske formulacije u koncentraciji od između > 21<£ 50 mM.
alkyl optionally substituted with one to three groups selected from the group consisting of halogen, alkoxy, alkoxyalkoxy, cycloalkyl and phenyl, and said pyridyl is optionally substituted with halogen, or its tautomer or a pharmaceutically acceptable salt thereof. 
alkil, izborno supstituiran s jednom do tri skupine, koje se bira iz skupine koju čine halogen, alkoksi, alkoksialkoksi, cikloalkil i fenil, i navedeni piridil je izborno supstituiran s halogenom, ili njegov tautomer ili njegova farmaceutski prihvatljiva sol.
The method according to any of claims 18 to 22, wherein the thermochemical reaction is shifted into the pay zone after the pay zone is heated up to about 300 °C. 
Postupak prema bilo kojem od patentnih zahtjeva 18 do 22, naznačen time, da se termokemijska reakcija pomiče u zonu iskoristivosti nakon što se zona iskoristivosti zagrije do oko 300 0C.
a trans-(+)-A9-tetrahydrocannabinol composition, comprising: allowing a composition comprising (±)-A9-tetrahydrocannabinol and an eluting solvent to separate on a chiral stationary phase to provide a trans-(+)-A9-tetrahydrocannabinol composition, 
separaciju trans-(+)-A9-tetrahidrokanabinola od alkoholno-kaustične faze; i kontaktiranje trans-(+)-A9-tetrahidrokanabinola iz koraka (b) sa trans-(-)-A9-tetrahidrokanabinolom i nepolarnim organskim otapalom da formiraju prvi sastav.
The polystyrene of claim 1, wherein the expandable polystyrene comprises a reflective additive in addition to alumina. 
Polistiren sukladno zahtjevu 1, naznačeno time da proširivi polistiren sadrži dodatni reflektirajući aditiv uz aluminijev oksid.
A process according to feature 1, wherein the compound of Formula IIa is a compound of Formula II and the sulphonating agent is tosyl chloride. 
Postupak prema zahtjevu 1, naznačen time da spoj formule Ila je spoj formule II i sredstvo za sulfoniranje je tosil klorid t>&
Fig. 15 shows a bisected log 10 which is sliced along the direction of the wood fiber. 
Slika 15 prikazuje prepolovljeno deblo 10 koje od kojega se režu kriške duž smjera drvenih vlakana.
The stable solution formulation of any one of claims 1 to 9, wherein the concentration of the GLP-1-Fc fusion protein is in the range of about 0.25 to 5 mg/mL, the concentration of citrate is about 10 mM, the concentration of polysorbate-80 is about 0.02% (w/v), the concentration of mannitol is about 4.6% (w/v) and the pH is in the range of 6.3 to 6.7. 
Stabilna otopinska formulacija u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačena time što koncentracija fuzijskog proteina GLP-1-Fc je u rasponu od otprilike 0,25 do 5 mg/ml, koncentracija citrata je otprilike 10 mM, koncentracija polisorbata-80 je otprilike 0,02% (tež./vol.), koncentracija manitola je otprilike 4,6% (tež./vol.), a pH je u rasponu od 6,3 do 6,7.
The hybrid formulation according to claim 1, characterized in that the methacrylic resin is trimethylpropane trimethylacrylate. 
Hibridna formulacija prema patentnom zahtjevu 1 ili 2, naznačena time, da metakrilna smola jest trimetilpropantrimetil akrilat.
The recombinant FSH preparation according to any one of claims 1 to 9, wherein the FSH has one or more of the following characteristics as can be determined in a granulose cell assay 
može stimulirati ili ko-stimulira sazrijevanje zametnih stanica biološkim procesom neovisnim od cAMP signalizacije; i/ili ima jednu ili više sljedećih karakteristika, što se može odrediti testiranjem granuloznih stanica
Features and advantages of the present invention will anyway be more readily understood from the description of a preferred, although not sole embodiment, which is given below by way of non-limiting example with reference to the accompanying drawings, in which: 
Karakteristike 1 prednosti ovog izuma ionako će se lakše razumjeti iz opisa poželjne, iako ne 1 jedine izvedbe, dane niže kao neograničujući primjer u vezi s pridruženim crtežima, gdje: Slika 1
Each purification stage have certain chromatography techniques and bead sizes that are best suited to the specific protein being purified. 
U svakom se koraku pročišćavanja koriste odgovarajuće kromatografske tehnike i veličine kuglica koja su najprikladnije za pročišćavanje odgovarajućeg proteina.
Use of E 74, wherein the pharmaceutical composition is further administered during a second treatment period that begins upon the end of the first treatment period and wherein the dose of the IL-17 antagonist to be administered is gradually reduced during the second treatment period. 
Uporaba u skladu sa zahtjevom 74, naznačena time, da se farmaceutski pripravak dalje primjenjuje tijekom drugog razdoblja liječenja koje započinje završetkom prvog razdoblja liječenja te se doza IL-17 antagonista koju treba primijeniti postupno smanjuje za vrijeme drugog razdoblja liječenja.
wherein a compound of formula (6a): is: 
O priprema slijedećim korakom A7: pri čemu spoj s formulom (6a):
an antibody which binds to the same epitope as that in DLL3 protein to which any of the antibodies (1) to (4) bind. 
(5) antitijelo koje se vezuje za isti epitop kao što je onaj što se nalazi u DLL3 proteinu za koji se vezuju bilo koja antitijela od (1) do (4).
A seal coat is a coating material which can be used to protect the enteric casing from possible chemical attack by any alkaline ingredients in the core. 
Brtvena ovojnica je tvar za oblaganje koja se može upotrijebiti da zaštiti enteričku ovojnicu od mogućeg kemijskog napada bilo kojeg od alkalnih sastojaka u jezgri.
The genetically modified mouse of claim 1, wherein the endogenous λ light chain immunoglobulin locus comprises the endogenous mouse enhancer 2.4 or the endogenous mouse 3' enhancer. 
Miš prema patentnom zahtjevu 1, naznačen time, što je lokus endogenog mišjeg lakog lanca λ izbrisan u potpunosti ili djelomično.
Method according to any one of claims 11 - 12, characterized in that it is provided for a part of gaseous fuel in liquid state when operating in gaseous fuel mode to be discharged from the fuel rail (2) and discharging the part of gaseous fuel in liquid phase from the fuel rail (2) when operating in gaseous fuel mode is a connection of fuel rail (2) with the gaseous fuel tank (6). 
Metoda u skladu sa bilo kojim od zahtjeva 11-12, naznačena time da je predviđeno za dio plinovitog goriva u tekućem stanju tijekom rada u načinu rada plinovitog goriva da se ispušta iz razvodnika goriva (2) i ispuštanje dijela plimovitog goriva u tekućoj fazi iz razvodnika goriva (2) tijekom rada u načinu rada plinovitog goriva pomoću spoja razvodnika goriva (2) sa spremnikom (6) plinovitog goriva.
A Streptococcus pneumoniae immunogenic composition comprising 10 or more capsular saccharides from different S . pneumoniae serotypes conjugated to 3 or more different carrier proteins, wherein the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT), serotype 18C capsular saccharide conjugated to tetanus toxoid (TT), serotype 1, 4, 5, 6B, 7F, 9V, 14 and 23F capsular saccharides conjugated to protein D from Haemophilus influenzae. 
Imunogeni pripravak protiv bakterije Streptococcus pneumoniae, koji sadrži 10 ili više saharida kapsule iz različitih serotipova bakterije S. pneumoniae, konjugiranih s proteinskim nosačem, te što sadrži 3 ili više različitih proteinskih nosača, naznačen time što pripravak sadrži: saharid iz kapsule serotipa 19F, konjugiran s difterijskim toksoidom (DT); saharid iz kapsule serotipa 18C, konjugiran s tetanusnim toksoidom (TT); saharidi iz kapsule serotipova 1, 4, 5, 6B, 7F, 9V, 14 1 23F, konjugirani s proteinom D iz bakterije Haemophilus influenzae.
The CD3-binding molecule of any one of claims 1-13, or of the pharmaceutical composition of claim 14, for use in treating cancer or an autoimmune or inflammatory disease; optionally wherein said autoimmune or inflammatory disease is selected from the group consisting of: type I insulin-dependent diabetes, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, myasthenia gravis, celiac's disease, Sjogren's syndrome, Grave's disease, Crohn's disease, autoimmune hepatitis, psoriasis, psoriatic arthritis, asthma, allergic rhinitis, effects from organ transplantation, and graft vs. host disease (GVHD). 
CD3-vezujuća molekula ili farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 17, naznačena time što navedena autoimuna ili inflamatorna bolest je izabrana iz grupe koja se sastoji od: inzulin ovisnog dijabetesa tip 1, reumatoidnog artritisa, sistemskog lupus eritematozisa, multiple skleroze, inflamatorne bolesti crijeva, mijastenije gravis, celijakije, Sjogrenovog sindroma, Gravesove bolesti, Crohnove bolesti, autoimunog hepatitisa, psorijaze, psorijatičkog artritisa, astme, alergijskog rinitisa, efekata transplantacije organa ili bolesti transplanta protiv domaćina (GVHD).
A method of transmitting a broadcasting signal to a receiver, the method comprising: encoding Physical Layer Pipe (PLP) data for carrying at least one service and Layer-1 (L1) signaling data for signaling the PLP data; 
Metoda za prijenos emitiranog signala, metoda obuhvaća: kodiranje podatka cijevi fizičke razine, PLP, za prijenos najmanje jednog servisa;
The present invention relates to compounds of formula (I): 
PATENTNI ZAHTJEVI zoom io Spoj formule (I):